Merck (MRK) Buys Rights To Anti-tau Antibody For Alzheimer
Zacks Investment Research | May 25, 2017 09:42PM ET
Merck & Co., Inc. (NYSE:MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Merck sees potential in the development and commercialization of the candidate for the treatment of Alzheimer’s disease (AD) and other neurological diseases. The company will make an undisclosed upfront payment to Teijin Pharma, which is also eligible to receive development, regulatory and sales milestone payments. Further, Teijin Pharma will receive royalties on product sales and retains an option to co-promote an approved product in Japan.
Merck’s shares are up 10.4% year to date, comparing unfavorably with an increase of 10.7% witnessed by the Zacks classified Large-Cap Pharma industry.
The addition of the anti-tau-antibody to its portfolio will complement Merck’s other AD candidates. This includes MK-6240, a tau ligand which is currently being assessed as a potential Positron Emission Tomography (PET) imaging agent for quantifying the brain burden of neurofibrillary tangle pathology in people with AD. Merck is also is evaluating verubecestat (MK-8931), a BACE1 inhibitor, to see if it can slow or stop the progression of AD.
Notably in Apr 2017, Biogen Inc. (NASDAQ:BIIB) announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb’s (NYSE:BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.
Biogen sees significant potential in the development and commercialization of BMS-986168 for the treatment of both AD and progressive supranuclear palsy (PSP). The deal is anticipated to be closed in the second quarter of 2017.
BMS-986168 is an antibody targeting extracellular tau, which is a protein that deposits in the brain associated with AD and other neurodegenerative tauopathies such as PSP. Biogen plans to soon initiate phase II studies for BMS-986168 in both AD and PSP.
However, we want to remind investors that in Feb 2017, the EPOCH study for Merck’s verubecestat was stopped after an interim analysis by an external Data Monitoring Committee (eDMC) indicated that the study might fail. While the EPOCH study was stopped due to lack of efficacy, another study, APECS, continues as the eDMC noted that the safety signals observed in the other study were not enough to stop APECS.
Get The News You Want
In a separate release, Merck also announced that it will collaborate with Optum, the health services business of UnitedHealth Group Incorporated (NYSE:UNH) , to advance value-based contracting of pharmaceuticals. Under outcomes-based risk sharing agreements (OBRSAs), health plans & other payers, the companies will reimburse drug manufacturers on basis of clinical outcomes achieved. Optum and Merck plan to publicly share analytic insights, findings and recommendations to help inform and facilitate the understanding and use of pragmatic approaches to OBRSAs in the health care system.
Zacks Rank and Other Key Picks
Merck currently carries a Zacks Rank #2 (Buy). You can see .
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.